MM is characterized by clonal proliferation of malignant plasma cells, monoclonal protein in the blood or urine, and associated organ dysfunction^1,2

• Predominantly affects older adults, with a higher prevalence in Black patients and males³
• A clonally heterogenous disease that contributes to treatment resistance and relapse⁴

IMWG criteria are used to diagnose MM⁵

• Treatment is indicated in patients with myeloma defining events (presence of CRAB or SLiM features)⁵

The R-ISS staging system is a risk-stratification algorithm that allows the identification of three prognostic groups with different outcomes⁶

MRD is an emerging parameter for measure of depth of response and as a prognostic marker⁷

Treatment of MM continues to evolve with CD38-based quadruplet regimens emerging as a preferred treatment option for TE NDMM and select TIE patients⁸

CAR-T and bispecific T-cell engagers have emerged as effective therapies in RRMM⁸

With the therapeutic improvement observed in the past few years, achievement of an operational cure is increasingly becoming a realistic goal⁹